# ATHENA: Natural History of Disease Study in Alport Syndrome Patients

> **NCT02136862** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 165 (actual)

## Conditions studied

- Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02136862
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-04
- **Primary completion:** 2017-12-18
- **Final completion:** 2017-12-18
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02136862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02136862, "ATHENA: Natural History of Disease Study in Alport Syndrome Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02136862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*